Reta is a common shorthand for retatrutide, and at the molecular level the peptide acts as a triple receptor agonist. That means it binds to and activates three separate receptors at once, the GLP-1 receptor, the GIP receptor, and the glucagon receptor. So what the reta peptide does, in scientific terms, is engage those three receptors and switch them on.
For the full receptor-by-receptor detail, see the companion guide on the retatrutide mechanism of action. retatrutide research peptides are supplied for laboratory research use only, and this article describes receptor pharmacology, not what the compound does in a person or any direction for use.
Reta is shorthand for retatrutide
The name reta, sometimes written reta peptide, refers to retatrutide, the peptide assigned the development code LY3437943. The two names describe the same molecule, so a question about what reta does is a question about what retatrutide does at its receptors.
Retatrutide is a synthetic peptide of 39 amino acids, supplied as a lyophilized research material. Recognizing that reta and retatrutide are the same thing is the first step to reading its pharmacology, since product listings and research notes may use either name.
Its core action is receptor agonism
The central thing the peptide does is act as an agonist, a molecule that binds a receptor and switches it on. Retatrutide binds the GLP-1, GIP, and glucagon receptors, all of which are G-protein-coupled receptors, and because it hits all three it is called a triple agonist rather than a single or dual agonist.
All three receptors signal through the same intracellular route. Activation turns on the enzyme adenylyl cyclase, which raises the level of cyclic AMP inside the cell, and cyclic AMP then activates protein kinase A. That shared cascade is the common language through which the three arms act.
What each receptor arm contributes
The three arms do related but distinct jobs at the receptor level. The GLP-1 arm is tied to glucose-dependent insulin signaling, slowed stomach emptying, and satiety signaling. The GIP arm is tied to glucose-dependent insulin secretion and to signaling in fat tissue, where the GIP receptor influences how fat is stored and broken down.
The glucagon arm is tied to glucose and lipid handling in the liver and to energy expenditure. Combining the three is the reason retatrutide is studied as a distinct compound, since it produces a broader pattern of receptor signaling than any single-receptor agonist.
How strongly it acts on each receptor
The three activities are not evenly weighted. In the discovery research, retatrutide behaved as a full agonist at all three human receptors, meaning it can produce each receptor’s maximum response, with its potency highest at the GIP receptor, next at the GLP-1 receptor, and lowest at the glucagon receptor.
That tuned balance is part of what the reta peptide does, because the relative strength at each receptor shapes how much each arm contributes. The companion mechanism-of-action article lists the measured potency values for readers who want the numbers.
Where to read the full mechanism
This is a plain-language summary of what the reta peptide does at its receptors, and the receptor pharmacology rests on primary research. Readers who want the source can review the phase 2 trial from the New England Journal of Medicine, which describes the compound as an agonist of the GIP, GLP-1, and glucagon receptors.
For the receptor potencies, the signaling detail, and the molecular basis, the companion mechanism-of-action article goes deeper. This page answers the direct question of what reta does at the level of its three receptors.
Research use only
This article summarizes what retatrutide research peptides. It is a scientific reference and is not a statement of regulatory approval, medical availability, or any instruction for use.
All products are supplied for research and development use only. They are not for human or veterinary use, and they are not intended to diagnose, treat, cure, or prevent any disease. Anyone using this material is responsible for handling it in line with institutional requirements and applicable law.